Action Potential Venture Capital

Action Potential Venture Capital is the corporate venture capital arm of GlaxoSmithKline, based in Cambridge, Massachusetts. It invests in bioelectronic medicines and related technologies that read or influence electrical signals in the nervous system. The firm aims to build a portfolio of five to seven companies over five years, focusing on startups pursuing bioelectronic medicine concepts, existing companies with peripheral nervous system interfaces via first-generation devices, and technology platforms that underpin these treatments. It operates in close connection with GSK’s Bioelectronics R&D unit, supporting research from early development toward patient-ready therapies. Imran Eba serves as its first partner, moving from GSK’s Worldwide Business Development organization to lead the effort.

Imran Eba

Partner

Juan-Pablo Mas

Partner

Suraj Mudichintala

Senior Associate

25 past transactions

MicroTransponder

Series F in 2025
MicroTransponder is a medical device company that develops and commercializes implantable neurostimulation platforms aimed at treating neurological conditions. The company focuses on vagus nerve stimulation to promote neuroplasticity and functional recovery, with products including the Serenity System for tinnitus and Vivistim, an FDA-approved therapy for ischemic stroke survivors with moderate to severe upper-limb impairment more than six months post-stroke. Founded in 2007 and headquartered in Austin, Texas, MicroTransponder's technology combines paired vagus nerve stimulation with wireless delivery of targeted electrical impulses to enhance recovery after neurological injury and disease.

Saluda Medical

Venture Round in 2025
Saluda Medical is a medical device company specializing in closed-loop neuromodulation therapies for chronic neurological conditions. Founded in 2010 and headquartered in Australia, the company develops innovative devices like Evoke, designed to optimize neural stimulation based on real-time feedback.

NeuSpera Medical

Series D in 2024
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.

Presidio Medical

Series C in 2023
Presidio Medical is a clinical-stage medical device company based in South San Francisco, California. It develops a neuromodulation platform intended to treat chronic pain by modulating neural activity and addressing disorders of neuronal function. The company pursues bioelectronic medicine to create a new class of therapeutic devices, combining biotechnology and neuromodulation to provide remedies for neural disorders.

Saluda Medical

Venture Round in 2023
Saluda Medical is a medical device company specializing in closed-loop neuromodulation therapies for chronic neurological conditions. Founded in 2010 and headquartered in Australia, the company develops innovative devices like Evoke, designed to optimize neural stimulation based on real-time feedback.

Onc.AI

Series A in 2023
Onc.AI, Inc. is a technology company founded in 2020 and headquartered in San Carlos, California. It specializes in clinical oncology, utilizing advanced software that integrates genomics, proteomics, and radiomics to enhance oncology diagnostics. By employing deep learning techniques, Onc.AI aims to provide actionable insights that improve treatment outcomes for cancer patients. The company's innovative approach seeks to advance the field of oncology through the development of comprehensive data-driven solutions.

Alpheus Medical

Series A in 2022
Alpheus Medical develops a sonodynamic therapy platform for solid tumors, combining a drug with a device activated by ultrasound to deliver targeted treatment for recurrent glioblastoma multiforme and other cancers. The non-invasive outpatient approach aims to avoid imaging and hospital admission while concentrating therapy on malignant tissues.

MicroTransponder

Series E in 2022
MicroTransponder is a medical device company that develops and commercializes implantable neurostimulation platforms aimed at treating neurological conditions. The company focuses on vagus nerve stimulation to promote neuroplasticity and functional recovery, with products including the Serenity System for tinnitus and Vivistim, an FDA-approved therapy for ischemic stroke survivors with moderate to severe upper-limb impairment more than six months post-stroke. Founded in 2007 and headquartered in Austin, Texas, MicroTransponder's technology combines paired vagus nerve stimulation with wireless delivery of targeted electrical impulses to enhance recovery after neurological injury and disease.

Alpheus Medical

Series A in 2021
Alpheus Medical develops a sonodynamic therapy platform for solid tumors, combining a drug with a device activated by ultrasound to deliver targeted treatment for recurrent glioblastoma multiforme and other cancers. The non-invasive outpatient approach aims to avoid imaging and hospital admission while concentrating therapy on malignant tissues.

NeuSpera Medical

Series C in 2021
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.

Exo

Series B in 2020
Exo is a medical device startup specializing in handheld ultrasound technology. It combines advanced materials, sensors, signal processing, and computation with semiconductor manufacturing economies to deliver affordable, high-quality imaging. This empowers healthcare professionals to make critical real-time decisions, enhancing patient outcomes.

Presidio Medical

Series B in 2020
Presidio Medical is a clinical-stage medical device company based in South San Francisco, California. It develops a neuromodulation platform intended to treat chronic pain by modulating neural activity and addressing disorders of neuronal function. The company pursues bioelectronic medicine to create a new class of therapeutic devices, combining biotechnology and neuromodulation to provide remedies for neural disorders.

CVRx

Venture Round in 2020
CVRx develops and markets implantable neuro-modulation therapies for treating high blood pressure and heart failure. Its flagship product, BAROSTIM NEO, triggers the body's natural reflex to regulate blood pressure, slowing heart failure progression. CVRx serves patients and healthcare professionals worldwide.

SetPoint Medical Corporation

Venture Round in 2019
SetPoint Medical Corporation is a clinical-stage medical device company developing implantable neuromodulation therapies to treat chronic inflammatory and autoimmune diseases. Its platform uses vagus nerve stimulation to activate the body's inflammatory reflex, aiming to produce a systemic immune-restorative effect and offer an alternative to drug therapy for conditions such as rheumatoid arthritis and inflammatory bowel disease. Based in Valencia, California.

Axon Therapies

Series A in 2019
Axon Therapies is a healthcare company focused on developing innovative solutions to address heart failure by targeting the sympathetic nervous system. The company has created the SAVM procedure, which utilizes a specialized device that allows clinicians to ablate the right greater splanchnic nerve through a minimally invasive catheter inserted via the groin. This procedure aims to reduce sympathetic nerve activity, restore balance in the circulatory system, and shift blood volume away from the heart, ultimately lowering heart pressures. By enabling rapid intervention, Axon Therapies enhances the likelihood of successful treatment outcomes for patients suffering from heart failure.

CVRx

Series G in 2019
CVRx develops and markets implantable neuro-modulation therapies for treating high blood pressure and heart failure. Its flagship product, BAROSTIM NEO, triggers the body's natural reflex to regulate blood pressure, slowing heart failure progression. CVRx serves patients and healthcare professionals worldwide.

NeuSpera Medical

Series B in 2019
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.

NeuSpera Medical

Series B in 2018
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.

Presidio Medical

Series A in 2018
Presidio Medical is a clinical-stage medical device company based in South San Francisco, California. It develops a neuromodulation platform intended to treat chronic pain by modulating neural activity and addressing disorders of neuronal function. The company pursues bioelectronic medicine to create a new class of therapeutic devices, combining biotechnology and neuromodulation to provide remedies for neural disorders.

SetPoint Medical Corporation

Series D in 2017
SetPoint Medical Corporation is a clinical-stage medical device company developing implantable neuromodulation therapies to treat chronic inflammatory and autoimmune diseases. Its platform uses vagus nerve stimulation to activate the body's inflammatory reflex, aiming to produce a systemic immune-restorative effect and offer an alternative to drug therapy for conditions such as rheumatoid arthritis and inflammatory bowel disease. Based in Valencia, California.

Saluda Medical

Series D in 2017
Saluda Medical is a medical device company specializing in closed-loop neuromodulation therapies for chronic neurological conditions. Founded in 2010 and headquartered in Australia, the company develops innovative devices like Evoke, designed to optimize neural stimulation based on real-time feedback.

Cala Health

Series B in 2016
Cala Health is a bioelectronic medicine company that develops wearable neuromodulation therapies for chronic diseases. Its primary product, Cala Trio therapy, is a non-invasive prescription treatment for essential tremor.

SetPoint Medical Corporation

Series C in 2015
SetPoint Medical Corporation is a clinical-stage medical device company developing implantable neuromodulation therapies to treat chronic inflammatory and autoimmune diseases. Its platform uses vagus nerve stimulation to activate the body's inflammatory reflex, aiming to produce a systemic immune-restorative effect and offer an alternative to drug therapy for conditions such as rheumatoid arthritis and inflammatory bowel disease. Based in Valencia, California.

SetPoint Medical Corporation

Series C in 2013
SetPoint Medical Corporation is a clinical-stage medical device company developing implantable neuromodulation therapies to treat chronic inflammatory and autoimmune diseases. Its platform uses vagus nerve stimulation to activate the body's inflammatory reflex, aiming to produce a systemic immune-restorative effect and offer an alternative to drug therapy for conditions such as rheumatoid arthritis and inflammatory bowel disease. Based in Valencia, California.

Alpheus Medical

Alpheus Medical develops a sonodynamic therapy platform for solid tumors, combining a drug with a device activated by ultrasound to deliver targeted treatment for recurrent glioblastoma multiforme and other cancers. The non-invasive outpatient approach aims to avoid imaging and hospital admission while concentrating therapy on malignant tissues.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.